Allison Bratzel
Stock Analyst at Piper Sandler
(4.76)
# 116
Out of 5,124 analysts
48
Total ratings
71.05%
Success rate
24.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Overweight | $28 → $30 | $7.95 | +277.36% | 1 | Nov 11, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $820 → $930 | $840.95 | +10.59% | 15 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $26 → $35 | $38.21 | -8.40% | 3 | Nov 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $70 → $77 | $79.11 | -2.67% | 3 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $82 → $102 | $98.77 | +3.27% | 3 | Nov 4, 2025 | |
| IOBT IO Biotech | Maintains: Overweight | $10 → $3 | $0.61 | +392.69% | 1 | Oct 22, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $52 → $51 | $44.05 | +15.78% | 4 | Sep 24, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $134.86 | -16.95% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $9.72 | +126.34% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $26.29 | +25.52% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $23.00 | +400.00% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $6 | $1.61 | +272.67% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $9.03 | +187.93% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $42.83 | -46.30% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $21.70 | +1.38% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $0.96 | +316.45% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $5.64 | +254.61% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $3.42 | +484.80% | 1 | Oct 13, 2023 |
MeiraGTx Holdings
Nov 11, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $7.95
Upside: +277.36%
argenx SE
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $840.95
Upside: +10.59%
Travere Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $26 → $35
Current: $38.21
Upside: -8.40%
Ionis Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $70 → $77
Current: $79.11
Upside: -2.67%
Incyte
Nov 4, 2025
Maintains: Overweight
Price Target: $82 → $102
Current: $98.77
Upside: +3.27%
IO Biotech
Oct 22, 2025
Maintains: Overweight
Price Target: $10 → $3
Current: $0.61
Upside: +392.69%
Scholar Rock Holding
Sep 24, 2025
Maintains: Overweight
Price Target: $52 → $51
Current: $44.05
Upside: +15.78%
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $134.86
Upside: -16.95%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $9.72
Upside: +126.34%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $26.29
Upside: +25.52%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $23.00
Upside: +400.00%
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $1.61
Upside: +272.67%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $9.03
Upside: +187.93%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $42.83
Upside: -46.30%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $21.70
Upside: +1.38%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $0.96
Upside: +316.45%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $5.64
Upside: +254.61%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.42
Upside: +484.80%